Armistice Capital LLC Has $9.30 Million Stock Position in Verrica Pharmaceuticals Inc. $VRCA

Armistice Capital LLC increased its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 75.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,118,925 shares of the company’s stock after acquiring an additional 479,732 shares during the quarter. Armistice Capital LLC owned about 7.00% of Verrica Pharmaceuticals worth $9,298,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Squarepoint Ops LLC bought a new position in Verrica Pharmaceuticals in the 4th quarter worth $276,000. OMERS ADMINISTRATION Corp bought a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth about $188,000. Marshall Wace LLP bought a new position in Verrica Pharmaceuticals during the 4th quarter valued at about $708,000. Walleye Capital LLC bought a new position in Verrica Pharmaceuticals during the 4th quarter valued at about $127,000. Finally, Affinity Asset Advisors LLC bought a new position in Verrica Pharmaceuticals during the 4th quarter valued at about $5,878,000. Institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA opened at $5.83 on Thursday. Verrica Pharmaceuticals Inc. has a 12 month low of $3.28 and a 12 month high of $9.82. The firm has a fifty day simple moving average of $6.29 and a 200 day simple moving average of $6.64. The stock has a market capitalization of $100.16 million, a price-to-earnings ratio of -5.66 and a beta of 1.49. The company has a current ratio of 2.10, a quick ratio of 1.98 and a debt-to-equity ratio of 0.03.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.18. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. The business had revenue of $5.02 million during the quarter, compared to analysts’ expectations of $4.51 million. Research analysts forecast that Verrica Pharmaceuticals Inc. will post -1.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. HC Wainwright began coverage on shares of Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price target for the company. Finally, Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Verrica Pharmaceuticals presently has an average rating of “Hold” and an average price target of $14.50.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.